ST Pharm Partners with LegoChem Biosciences for ADC Linker Production
Signing of Contract for ADC Linker Manufacturing Process Research and Outsourcing
ST Pharm, led by CEO Kyungjin Kim, announced on March 11th a joint research and manufacturing agreement with LegoChem Biosciences, under CEO Yong-Zu Kim, aimed at enhancing the production process of Antibody-Drug Conjugate (ADC) linkers.
Through this collaboration, ST Pharm will provide Contract Development and Manufacturing Organization (CDMO) services, encompassing process optimization research for critical linkers utilized in LegoChem Bio's ADC ConjuALL platform, as well as cGMP-based production.
LegoChem Biosciences stands out for its robust Research and Development (R&D) capabilities in ADC technology and synthetic drugs. The company has inked a total of 13 technology transfer contracts with global pharmaceutical firms, valued at up to $6.6 billion. Leveraging its ADC platform technology, LegoChem Bio has demonstrated superior plasma stability and precise intracellular release within cancer cells, showcasing its technical prowess and efficacy with minimal side effects in recent clinical trials.
ST Pharm, a specialty pharmaceutical company certified by the U.S. Food and Drug Administration (FDA) for current Good Manufacturing Practice (cGMP), boasts the ability to produce small-scale clinical samples as well as commercial quantities ranging from small batches to tons. With a track record of producing over 50 tons of small molecule active pharmaceutical ingredients annually and a wealth of technical expertise, the company positions itself as a global CDMO certified by the FDA for both small molecule active pharmaceutical ingredients and oligo APIs.
Kyungjin Kim, CEO of ST Pharm, affirmed, "Our firm is a cGMP active pharmaceutical ingredient (API) specialty CDMO, showcasing production capabilities through partnerships with multinational pharmaceutical companies." He emphasized, "With our exceptional technical expertise and quality management capabilities, we are committed to reliably supplying LegoChem Biosciences' ADC linkers."
Yong-Zu Kim, CEO of LegoChem Biosciences, remarked, "Through our collaboration with ST Pharm, we are establishing a domestic source for core components of our ADC linkers in South Korea, contributing to the development of a comprehensive South Korean supply chain for all ADC elements, including antibodies, linkers, and payloads." He added, "In the coming years, we aim for mutual growth by closely collaborating with outstanding South Korean firms like ST Pharm, renowned for their process development and manufacturing capabilities."